PHARMACYTE BIOTECH INC (OTCMKTS:PMCB) Sellers Covered 65.25% of Their Shorts

August 10, 2018 - By Robert Shackelford

PharmaCyte Biotech, Inc. (OTCMKTS:PMCB) Logo

The stock of PHARMACYTE BIOTECH INC (OTCMKTS:PMCB) registered a decrease of 65.25% in short interest. PMCB’s total short interest was 17,200 shares in August as published by FINRA. Its down 65.25% from 49,500 shares, reported previously.

The stock increased 0.20% or $0.0001 during the last trading session, reaching $0.0575. About shares traded. PharmaCyte Biotech, Inc. (OTCMKTS:PMCB) has 0.00% since August 10, 2017 and is . It has underperformed by 12.57% the S&P500.

PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. The company has market cap of $59.86 million. The Company’s cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. It currently has negative earnings. The firm is developing therapies for pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.